News Center

Events

Other Event

Big Data and Ethics

March 15, 2018 12:00pm - 5:00pm

Dr. Jennifer Miller speaks at Baruch’s Zicklin Center for Corporate Integrity


Location

New York, NY

http://www.corporatecomm.org/event/big-data-and-ethics/

More

Other Event

Drug Accessibility and Pricing Symposium

March 19, 2018

Dr. Jennifer Miller speaks at Johns Hopkins Carey Business School

Monday, March 19th

 

Location

Baltimore, MD

More

All Events

Blog

New York Times interviews our founder, Jennifer Miller, on FDA's clinical trial transparency pilot

The New York Times interviewed our founder, Jennifer Miller, on FDA Commissioner Dr. Scott Gottlieb's clinical trial transparency initiatives. She discussed his new pilot, launched last month, which selects 9 recently-approved drugs, whose sponsors (generally pharmaceutical companies) volunteer to participate, to post portions of Clinical Study Reports (CSRs) from their pivotal trials on FDA's website…

February 12, 2018

Big Data Probably Knows More About You Than Your Friends Do

This week we focused on the ethics of Big Data, publishing an article titled, Big Data Probably Knows More About You Than Your Friends Do, in Leaps Mag. The article discusses the promises and perils of big data and concludes with a way to manage your data wealth.  To read the full article click here.

February 7, 2018

All Posts

Publications

Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies

Miller JE, Wilenzick M, Ritcey N, et al. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies. BMJ Open 2017;0:e017917. doi:10.1136/ bmjopen-2017-017917

Cross-sectional descriptive analysis of all clinical trials supporting 2014 Food and Drugs Administration (FDA)-approved new drug applications (NDAs) for novel drugs sponsored by large companies.

Characterizing Expanded Access and Compassionate Use Programs for Experimental Drugs

Miller JE, Ross JS, Moch KI, Caplan AL. Characterizing expanded access and compassionate use programs for experimental drugs. (2017). BMC Res Notes. DOI: 10.1186/s13104-017-2687-5.

Most (76%) provided drugs in expanded access programs eventually received FDA approval. Thus, provided drugs in registered expanded access programs are, more times than not, eventually deemed safe by the FDA.

All Publications

Press and Media Inquires

All press and media inquiries should be directed to:

Maggie Beller, Russo Partners LLC
maggie.beller@russopartnersllc.com
646-942-5631

Naomi Bowen, Behrman Communications
bioethics@behrmanpr.com
212-986-7000 ext. 119

Newsletter